Kim A. Margolin
Experienced in Arteriovenous Malformation

Dr. Kim A. Margolin

Oncology | Hematology Oncology
Providence Saint Johns Medical Foundation
2121 Santa Monica Blvd, 
Santa Monica, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Arteriovenous Malformation
Providence Saint Johns Medical Foundation
2121 Santa Monica Blvd, 
Santa Monica, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kim Margolin is an Oncologist and a Hematologist Oncology provider in Santa Monica, California. Dr. Margolin is rated as an Experienced provider by MediFind in the treatment of Arteriovenous Malformation. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Metastatic Brain Tumor, and Choriocarcinoma.

Her clinical research consists of co-authoring 142 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Arteriovenous Malformation.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Saint John's Health Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

PROVIDENCE SAINT JOHNS MEDICAL FOUNDATION
2121 Santa Monica Blvd, Santa Monica, CA 90404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Procedure, Biological, Other
Study Drugs: Cyclophosphamide, Fludarabine Phosphate, IL13Ralpha2-Specific Hinge-Optimized 4-1BB-co-Stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Recombinant Interleukin-2
Study Phase: Phase 1
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)
An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: IO102-IO103, Pembrolizumab
Study Phase: Phase 3
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

141 Total Publications

Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.
Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.
Journal: Journal for immunotherapy of cancer
Published: May 06, 2025
Similar Doctors
Experienced in Arteriovenous Malformation
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology
Experienced in Arteriovenous Malformation
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (16.0 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Casey O'connell is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. O'connell is rated as an Elite provider by MediFind in the treatment of Arteriovenous Malformation. Her top areas of expertise are Polycythemia Vera, Myelofibrosis, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Splenectomy.

Experienced in Arteriovenous Malformation
Dr. Charisma Mylavarapu
Hematology Oncology | Hematology | Oncology
Experienced in Arteriovenous Malformation
Dr. Charisma Mylavarapu
Hematology Oncology | Hematology | Oncology

City Of Hope Medical Foundation

1601 Avocado Ave, 
Newport Beach, CA 
 (45.3 miles away)
949-763-2204
Languages Spoken:
English
See accepted insurances

Charisma Mylavarapu is a Hematologist Oncology specialist and a Hematologist in Newport Beach, California. Dr. Mylavarapu is rated as an Experienced provider by MediFind in the treatment of Arteriovenous Malformation. Her top areas of expertise are Hereditary Hemorrhagic Telangiectasia and Arteriovenous Malformation.

Ronald Tang
Experienced in Arteriovenous Malformation
Dr. Ronald Tang
Oncology | Hematology
Experienced in Arteriovenous Malformation
Dr. Ronald Tang
Oncology | Hematology

Los Angeles Cancer Network

50 Alessandro Place, Ste 310 South Tower, 
Pasadena, CA 
 (20.0 miles away)
626-288-0008
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Tang is a Hematologist and an Oncologist in Pasadena, California. Dr. Tang is rated as a Distinguished provider by MediFind in the treatment of Arteriovenous Malformation. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Neuroendocrine Carcinoma of the Cervix, and Cervical Cancer. Dr. Tang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Margolin's expertise for a condition
ConditionClose
View All 53 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile